Business
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France.","length":300,"tagName":"p"},{"type":"text","content":"Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented:"We are delighted to place this first order of the Nu.Q® Cancer assays to complete the internal certification process ahead of introducing the test into routine clinical practice in our hospital network for cancer management.","length":376,"tagName":"p"},{"type":"text","content":""We have worked closely with the Volition team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients. Our results indicate that measuring methylated nucleosome biomarker levels at Non Small Cell Lung Cancer diagnosis can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care.1-3"","length":481,"tagName":"p"},{"type":"text","content":"Dr. Andrew Retter, Chief Medical Officer, Volition, added:"Research conducted by the team at Lyon demonstrates that Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey. By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.","length":503,"tagName":"p"},{"type":"text","content":""Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring."","length":195,"tagName":"p"},{"type":"text","content":"Mr. Gael Forterre, Chief Commercial Officer, Volition concluded:"This is a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. We are now on the path to the first use of Nu.Q®...